Physician profile
Gary E Machado
NPI 1689989584
$5,742.11
in general payments reported to CMS, 2019-2025
30 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $413 · 2021: $873 · 2022: $710 · 2023: $236 · 2024: $504 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $902.56 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $722.80 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $619.35 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $470.45 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $387.36 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.57 | 2019-2024 | |
| Glaxosmithkline, LLC. | $371.89 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $240.56 | 2019-2025 | Ozempic, Wegovy |
| Biohaven Pharmaceutical Holding Company Ltd. | $167.93 | 2022 | |
| Allergan, INC. | $156.34 | 2019-2020 | |
| Pfizer INC. | $147.38 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $141.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.19 | 2022-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $132.84 | 2019 | |
| Exact Sciences Corporation | $128.59 | 2023-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $125.00 | 2020 | |
| Amarin Pharma, INC. | $85.12 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $56.15 | 2019 | |
| Merck Sharp & Dohme LLC | $55.33 | 2019-2025 | Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $46.45 | 2019 | |
| Astellas Pharma US INC | $44.43 | 2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $44.29 | 2019-2021 | |
| Abbott Laboratories | $42.34 | 2025 | Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $35.43 | 2025 | Symbravo, Auvelity |
| Dynavax Technologies Corporation | $19.45 | 2025 | Heplisav-B |
| Shire North American Group INC | $18.64 | 2019 | |
| Corcept Therapeutics | $16.18 | 2025 | Korlym |
| Horizon Therapeutics Plc | $15.88 | 2023 | Krystexxa |
| Genentech USA, INC. | $15.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Machado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.